Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Year
  • 1
    In: Annals of Oncology, 2017, Vol. 28(suppl9)
    ISSN: 0923-7534
    E-ISSN: 1569-8041
    Source: Oxford University Press
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Annals of Oncology, 2015, Vol. 26(suppl7), pp.vii12-vii12
    Keywords: Medicine;
    ISSN: 0923-7534
    E-ISSN: 1569-8041
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Annals of Oncology, 2018, Vol. 29(suppl7)
    Keywords: Medicine;
    ISSN: 0923-7534
    E-ISSN: 1569-8041
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Annals of Oncology, 2017, Vol. 28(suppl9)
    ISSN: 0923-7534
    E-ISSN: 1569-8041
    Source: Oxford University Press
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Annals of Oncology, 2015, Vol. 26(suppl7), pp.vii21-vii21
    Keywords: Medicine;
    ISSN: 0923-7534
    E-ISSN: 1569-8041
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Annals of Oncology, 2018, Vol. 29(suppl7)
    Keywords: Medicine;
    ISSN: 0923-7534
    E-ISSN: 1569-8041
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: Japanese
    In: Gan to kagaku ryoho. Cancer & chemotherapy, September 2016, Vol.43(9), pp.1041-7
    Description: Immune checkpoint inhibitors which have been currently approved on malignant melanoma and non-small cell lung cancer in Japan, are having completely different mechanism from the conventional anti-neoplastic agents such as cytotoxic anticancer agents or molecular targeting agents. Therefore, although the response rate is not so high, the patterns of anti-tumor effect such as long-term survival or durable response and unique toxicity profiles to stimulate autoimmune response are quite distinguished. It has been found to be significantly different from conventional anti-neoplastic agents. The results of current clinical trials using immune checkpoint inhibitors for gastrointestinal tract cancers, promises to gain new promising treatment options near future. The clarification of the biomarkers and development of combination therapy is strongly warranted in the future.
    Keywords: Antineoplastic Agents -- Therapeutic Use ; Esophageal Neoplasms -- Drug Therapy ; Stomach Neoplasms -- Drug Therapy
    ISSN: 0385-0684
    Source: MEDLINE/PubMed (U.S. National Library of Medicine)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: Japanese
    In: Gan to kagaku ryoho. Cancer & chemotherapy, April 2013, Vol.40(4), pp.435-9
    Description: In recent years, active new agents have been introduced clinically against colorectal cancer and overall survivals of chemotherapy for metastatic colorectal cancer treatment much improved. For the appropriate treatment and management of targeted therapy with various side effects which is not seen in the anti-cancer agent, the cooperation of physicians, pharmacists and nurses has become mandatory. Furthermore, deep patients understanding for their diseases and treatments and good adherence of oral agents are strongly needed. In addition, liver surgeons in cases of possible hepatectomy and medical social workers (MSW) in case of the problems of high-cost medical care or the transition to palliative care are also required. In this way, the team medicine has become essential in order to continue to practice the appropriate chemotherapy for colorectal cancer. I would like to mention the attempt of Aichi Prefecture which has launched a system to support the team medicine through multicenter, multidisciplinary, and regional cooperation.
    Keywords: Patient Care Team ; Colorectal Neoplasms -- Drug Therapy
    ISSN: 0385-0684
    Source: MEDLINE/PubMed (U.S. National Library of Medicine)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: Japanese
    In: 日本大腸肛門病学会雑誌, 2018, Vol.71(10), pp.406-416
    Description: 癌領域に免疫チェックポイント阻害薬(ICI)が登場したことにより,現在,各癌種の治療体系は大きな変貌を遂げた.とくに悪性黒色腫や非小細胞肺癌では一次治療の標準治療を塗り替えるほどのパラダイムシフトが起きている.大腸癌を含むMSI-HもしくはdMMR固形腫瘍においても同様であり,ICIは極めて高い効果を示し,ICI単独療法では低毒性であり,効果とのバランスにおいて有望な治療法として確立した.治療に先立ちMSIもしくはdMMR検査を行う際には,事前に本検査がリンチ症候群のスクリーニングにもなりえる点を説明し,陽性であった場合には遺伝カウンセリングと確定診断のための遺伝学的検査(自費診療)への対応が必要となることを想定した体制整備が求められることに留意すべきである.
    Description: Currently, the treatment system and standard of care for each type of cancer have dramatically changed due to the development of immune checkpoint inhibitors (ICIs). For MSI-H or dMMR for solid tumors including colorectal cancer, ICIs show extremely high effect with acceptable toxicities, so ICIs against MSI-H cancers have been established as a promising therapeutic method. However, there are some difficulties. When conducting MSI testing or dMMR immunohistochemical staining prior to ICI therapy, a doctor or medical staff should explain to the patient the necessity of genetic counseling and genetic examination for a definitive diagnosis in case of MSI-H or dMMR. Accordingly, it will be necessary to carry out genetic testing and treatment by ICIs under appropriate medical circumstances (facilities, doctors, and other medical staffs).
    Keywords: 免疫チェックポイント阻害薬 ; 大腸癌 ; MSI-H ; dMMR ; 体細胞変異数(TMB) ; Immune Checkpoint Inhibitor ; Colorectal Cancer ; Msi&Amp;Ndash;H ; Dmmr ; Tumor Mutation Burden (Tmb)
    ISSN: 0047-1801
    E-ISSN: 18829619
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: Japanese
    In: Gan to kagaku ryoho. Cancer & chemotherapy, November 2017, Vol.44(11), pp.984-985
    Description: 本号のcurrent organ topicsは, 2016年11月に同時に発刊された大腸癌に関する3種類のガイドライン/ガイダンスについて, それぞれ中心的にかかわった3名の方々に執筆をお願いし, ご解説いただいた. まず, 「遺伝性大腸癌診療ガイドライン2016年版(大腸癌研究会/編)」を, 埼玉医科大学総合医療センターの石田秀行先生らからご寄稿いただいた. 特に, 大腸癌研究会の家族性大腸癌委員会の多施設共同研究, HNPCC第2次プロジェクトなどの日本のデータを数多く引用して, FAPやリンチ症候群の各論やCQに盛り込んでいただいた点など, 2012年版からの改訂ポイントを中心にご解説いただいた. さらにリンチ症候群におけるBRAFV600E検査やMMR検査(あるいはマイクロサテライト不安定性検査)について, 加筆された点を詳細に解説いただいた. この解説を通読して, 国内外に類書のまったくない領域の本ガイドラインの作成が, さぞかし大変でご苦労も多かったであろうと痛感させられた.
    Keywords: Colonic Neoplasms ; Periodicals As Topic ; Practice Guidelines As Topic ; Rectal Neoplasms
    ISSN: 0385-0684
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages